Stanford Investment Group’s Myriad Genetics MYGN Stock Holding History

Stanford Investment Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-225	Closed	-$5K	–	401
2016 Q3	$5K	Buy	+225	New	+$5.71K	﹤0.01%	366

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Stanford Investment Group's MYGN Position: Q4 2016 in Review

Stanford Investment Group sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 225 shares — an estimated $5K sold.

Stanford Investment Group first reported a position in MYGN in Q3 2016 and held it in 1 quarter. The position peaked at $5K in Q3 2016. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

Stanford Investment Group reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
Stanford Investment Group sold 225 Myriad Genetics shares in Q4 2016, an estimated $5K.
Stanford Investment Group first reported a position in Myriad Genetics in Q3 2016 and held it in 1 quarter.
Stanford Investment Group's Myriad Genetics position peaked at $5K in Q3 2016.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Stanford Investment Group's 13F filing for Q4 2016, filed 2 Feb 2017.